HAP Trading’s Sarepta Therapeutics SRPT Stock Holding History

HAP Trading’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-41,077	Closed	-$6.49M	–	808
2024 Q2	$6.49M	Buy	41,077 +30,054	+273%	+$3.86M	0.77%	28
2024 Q1	$1.43M	Buy	+11,023	New	+$1.35M	0.16%	98
2021 Q2	–	Sell	-10,182	Closed	-$772K	–	2679
2021 Q1	$759K	Sell	10,182 -441	-4%	-$40.7K	0.04%	377
2020 Q4	$1.81M	Buy	+10,623	New	+$1.57M	0.05%	287
2019 Q3	–	Sell	-50,466	Closed	-$5.96M	–	1373
2019 Q2	$7.67M	Buy	+50,466	New	+$6.13M	0.59%	40
2019 Q1	–	Sell	-15,294	Closed	-$1.97M	–	1345
2018 Q4	$1.67M	Sell	15,294 -2,409	-14%	-$301K	0.11%	170
2018 Q3	$2.86M	Buy	+17,703	New	+$2.42M	0.18%	120
2017 Q1	–	Sell	-36,556	Closed	-$1M	–	1235
2016 Q4	$1M	Buy	+36,556	New	+$1.47M	0.05%	250
2013 Q3	–	Sell	-66,619	Closed	-$2.57M	–	879
2013 Q2	$2.53M	Buy	+66,619	New	+$2.38M	0.09%	206

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

HAP Trading's SRPT Position: Q3 2024 in Review

HAP Trading sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 41,077 shares — an estimated $6.49M sold.

HAP Trading first reported a position in SRPT in Q2 2013 and held it in 9 quarters. The position peaked at $7.67M in Q2 2019. 458 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

HAP Trading reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
HAP Trading sold 41,077 Sarepta Therapeutics shares in Q3 2024, an estimated $6.49M.
HAP Trading first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 9 quarters.
HAP Trading's Sarepta Therapeutics position peaked at $7.67M in Q2 2019.
458 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on HAP Trading's 13F filing for Q3 2024, filed 12 Nov 2024.